A LinkedIn post from Tubulis indicates the company plans to participate in the Therapeutic Frontiers in Medicine 2026 conference in Frankfurt am Main from April 13–16. The post notes that Associate Director of Chemistry & Early Discovery, Jan G. Felber, is scheduled to present the proprietary conjugation technology behind Tubulis’ Alco5 platform.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
According to the post, this platform is described as enabling the development of degrader antibody conjugates by facilitating efficient delivery of hydroxy-containing payloads. For investors, this conference presence may signal ongoing investment in differentiated antibody-drug conjugate technologies, which could support future partnering opportunities and enhance Tubulis’ positioning in next-generation targeted oncology and therapeutic modalities.